The US Food and Drug Administration (FDA) has cleared Vaxcyte’s infant Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD). The company plans to initiate the infant Phase II study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data […]
